Alnylam Pharmaceuticals, Inc.

NASDAQ:ALNY

Biotechnology

Healthcare
$149.40 -2.22%

-$6.27 today

Market cap
$20.01B
Beta
0.27
P/E (TTM)
63.6
EPS (TTM)
$4.34
52W Low $273.11High $495.55

Volume 2.52M

Average 1.11M

ALNY Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Alnylam Pharmaceuticals, Inc.NASDAQ: ALNY

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin narrows to 76.9%

Gross margin was 76.9% in Q2 FY2026, down 4.6 pp from a year earlier. On a trailing-twelve-month basis it was 79.7%, down 3.9 pp year over year. Over 3 fiscal years it narrowed by 2.0 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
76.9%-5.0 pp QoQ
Last fiscal yearDec 2025
81.8%-3.8 pp YoY
LTMJun 2026
79.7%-3.9 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-4.6 pp——
1 year-3.8 pp——
3 years-2.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
81.8%
Year-over-year change
-3.8pp

Gross Margin vs competitors

How ALNY compares with its peers on the latest reported figures

  • ALNY's LTM Jun 2026 gross margin of 79.7% is the 4th highest of the 6 companies compared; the peer median is 93.8%.
  • Its year-over-year change of -3.9 pp is the 4th highest of 5, against a peer median of -0.5 pp.
  • Over three fiscal years its change of -2.0 pp compares with a peer median of +0.7 pp.
ALNY Competitors Peer median
Gross Margin for ALNY and competitors
Company Period LTM level YoY 3-year change
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 202699.6% -0.4 pp+4.8 pp
IONSIonis Pharmaceuticals, Inc.LTM Sep 202698.2% -0.6 pp+0.7 pp
WVEWave Life Sciences Ltd.LTM Mar 202693.8% -4.1 pp-20.7 pp
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 202679.7% -3.9 pp-2.0 pp
SLNSilence Therapeutics plcLTM Mar 202666.4% —+23.7 pp
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-153.7% +248.0 pp-9.0 pp
Peer median (excluding ALNY) 93.8%-0.5 pp+0.7 pp

Competitors are the stored peer set for ALNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue844.29M1.04B1.83B2.25B3.71B
Cost of Revenue140.14M168.82M310.41M323.37M677.17M
Gross Profit704.14M868.6M1.52B1.92B3.04B
Gross Margin83.4%83.7%83.0%85.6%81.8%
Research & Development792.16M883.02M1B1.13B1.32B
Selling, General & Admin620.64M770.66M795.65M975.53M1.21B
Operating Expenses1.41B1.65B1.8B2.1B2.54B
Depreciation & Amortization47.57M44.47M54.05M56.67M55.66M
EBITDA(661.56M)(926.56M)(258.24M)(178.85M)631.44M
EBITDA Margin-78.4%-89.3%-14.1%-8.0%17.0%
Operating Income(708.65M)(785.07M)(282.18M)(176.89M)501.58M
Operating Margin-83.9%-75.7%-15.4%-7.9%13.5%
Interest Income1.58M24.81M95.56M121.99M111.47M
Interest Expense143.02M155.97M121.22M141.86M252.63M
Other Income / Expenses(143.49M)(341.92M)(151.34M)(200.49M)(178.43M)
Income Before Tax(852.14M)(1.13B)(433.52M)(377.38M)323.15M
Pre-Tax Margin-100.9%-108.6%-23.7%-16.8%8.7%
Income Tax Expense680K4.16M6.73M(99.22M)9.41M
Net Income(852.82M)(1.13B)(440.24M)(278.16M)313.75M
Net Margin-101.0%-109.0%-24.1%-12.4%8.4%
EPS (Basic)(7.20)(9.30)(3.52)(2.18)2.39
EPS (Diluted)(7.20)(9.30)(3.52)(2.18)2.33
Weighted Avg Shares118.45M121.69M124.91M127.65M131M
Weighted Avg Shares (Diluted)118.45M121.69M124.91M127.65M134.68M

Alnylam Pharmaceuticals, Inc.

NASDAQ:ALNY

Intrinsic Alpha fair value

Locked

Current Price

$149.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.